Saxenburgh Medisch Centrum

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Heart failure4 trials
• Atrial fibrillation3 trials
• Chronic kidney disease2 trials
• Stroke2 trials
• Familial hypercholesterolaemia1 trial
• High blood pressure1 trial
• Hypothyroidism1 trial
• Multiple myeloma1 trial
• Obesity1 trial
• Prostate cancer1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 39 trials
• Phase 23 trials

Status

• Recruiting5 trials
• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting2 trials

Lead sponsor

• Cardurion Pharmaceuticals Inc.2 trials
• AstraZeneca1 trial
• Bayer AG1 trial
• Cardurion Pharmaceuticals, Inc.1 trial
• Comprehensive Cancer Centre The Netherlands1 trial
• and 8 more

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

  2025-525033-31-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  T3-4-Hypo trial

  2024-513883-24-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· AstraZeneca· Source

• Recruiting

  High-Risk prostatE Cancer radiatiOn Versus surgERy

  NCT05931419· Comprehensive Cancer Centre The Netherlands· Source

  Contact: Berdine Heesterman, MD, PhD

• Active, not recruiting

  The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

  NCT05374291· Phase 3· University Medical Center Groningen· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Heart failure1 recruiting
• Hypothyroidism1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source